US PRE-MARKET MOVERS: MSFT/META/TSLA, NVDA, AMZN, AI, AMAT, RGNX, STX, TXN, ASML, SBUX, T, PPG, ELV, QRVO

The pre-market trading updates reflect significant movements in key tech stocks, particularly as Nvidia's approval for AI chip imports from China boosts sentiment around AI and data storage, evidenced by STX's strong performance.

Newsquawk StaffPublished On the live feed at 4 more headlines followed before this page went public
Newsquawk headlinesUTC

US BROKER MOVES: AMAT upgraded at Mizuho; WAL downgraded at JPMorgan

GE Vernova (GEV) expect Y/Y growth in gas equipment orders in Q1 for the power unit; failure to install 11 turbines could cut 2026 wind revenue by c. USD 250mln - conference call

US PRE-MARKET MOVERS: MSFT/META/TSLA, NVDA, AMZN, AI, AMAT, RGNX, STX, TXN, ASML, SBUX, T, PPG, ELV, QRVO

Starbucks (SBUX) Q1 2026 (USD): Adj. EPS 0.56 (exp. 0.59), Revenue 9.9bln (exp. 9.65bln); comp sales +4% (exp. 1.88%)

Biogen (BIIB) announced that the US FDA has granted Breakthrough Therapy Designation for litifilimab for the treatment of cutaneous lupus erythematosus.

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

ES +0.2% NQ +0.8% RTY +0.4%

  • MSFT +0.3% META -0.2% TSLA +0.2%: Ahead of earnings after-hours
  • NVDA +2%: China approved first batch of H200 AI chips for import, covering several hundred thousand
  • AMZN +0.4%: Cuts 16k jobs globally to undo pandemic-era hiring amid AI push
  • AI +15%: Is in talks to merge with startup Automation Anywhere
  • AMAT +4%: Upgraded at Mizuho
  • RGNX -35%: FDA halts RGNX Gene therapy trials after brain tumour found in patient

Earnings

  • STX +9%: Q metrics beat & issued stronger guidance, supported by robust AI-driven demand for data storage
  • TXN +8%: Stronger than exp. Q1 outlook, signalling a recovery in demand for industrial equipment & vehicles
  • ASML +5.7%: Rev., profit topped, orders reached a record & strong guidance; Announced share buyback of up to €12bln
  • SBUX +5%: Rev. & comp. sales surpassed exp. w/ better than exp. FY comp. sales view
  • T +3.2%: Stellar report & solid FY profit view
  • PPG -2%: Profit missed & issued cautious outlook
  • ELV -8%: Top line weak & FY bottom line guidance missed
  • QRVO -10%: Light next Q guidance
Context

Conversely, RGNX’s drastic drop due to halted trials highlights risks associated with biotech, while mixed earnings reports from major companies like PPG and ELV signal potential headwinds in specific sectors. Overall, this presents a cautiously optimistic outlook with strong tech fundamentals overshadowing some of the weaker performances in other areas.

Related headlines

The whole workspace, free to try.

Try it free